Elevated E2F2 expression promotes proliferation and confers gemcitabine resistance in pancreatic cancer [37] and is also elevated in patients with RCC, suggesting its potential utility as a diagnostic biomarker [38]. The gene discussed is E2F2; the disease is renal cell carcinoma.